Neurobiology of Disease (Aug 2022)

NADPH oxidase 2 activity in Parkinson's disease

  • Matthew T. Keeney,
  • Eric K. Hoffman,
  • Kyle Farmer,
  • Christopher R. Bodle,
  • Marco Fazzari,
  • Alevtina Zharikov,
  • Sandra L. Castro,
  • Xiaoping Hu,
  • Amanda Mortimer,
  • Julia K. Kofler,
  • Eugenia Cifuentes-Pagano,
  • Patrick J. Pagano,
  • Edward A. Burton,
  • Teresa G. Hastings,
  • J. Timothy Greenamyre,
  • Roberto Di Maio

Journal volume & issue
Vol. 170
p. 105754

Abstract

Read online

Mitochondrial dysfunction and oxidative stress are strongly implicated in Parkinson's disease (PD) pathogenesis and there is evidence that mitochondrially-generated superoxide can activate NADPH oxidase 2 (NOX2). Although NOX2 has been examined in the context of PD, most attention has focused on glial NOX2, and the role of neuronal NOX2 in PD remains to be defined. Additionally, pharmacological NOX2 inhibitors have typically lacked specificity. Here we devised and validated a proximity ligation assay for NOX2 activity and demonstrated that in human PD and two animal models thereof, both neuronal and microglial NOX2 are highly active in substantia nigra under chronic conditions. However, in acute and sub-acute PD models, we observed neuronal, but not microglial NOX2 activation, suggesting that neuronal NOX2 may play a primary role in the early stages of the disease. Aberrant NOX2 activity is responsible for the formation of oxidative stress-related post-translational modifications of α-synuclein, and impaired mitochondrial protein import in vitro in primary ventral midbrain neuronal cultures and in vivo in nigrostriatal neurons in rats. In a rat model, administration of a brain-penetrant, highly specific NOX2 inhibitor prevented NOX2 activation in nigrostriatal neurons and its downstream effects in vivo, such as activation of leucine-rich repeat kinase 2 (LRRK2). We conclude that NOX2 is an important enzyme that contributes to progressive oxidative damage which in turn can lead to α-synuclein accumulation, mitochondrial protein import impairment, and LRRK2 activation. In this context, NOX2 inhibitors hold potential as a disease-modifying therapy in PD.

Keywords